ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1373	National Cancer Institute	Html	en	Cervical Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for cervical cancer.	Obstet Gynecol 0.581628 Hysterectomy-corrected cervical cancer 0.555295 HPV DNA testing 0.788756 cervical cancer worldwide 0.552556 American Cancer Society 0.524538 cervical sample collection 0.524565 Int J Cancer 0.522908 cervical screening 0.611205 cervical neoplasia 0.571227 cervical screening studies 0.563298 human papillomavirus dna 0.532798 mild cervical dysplasia 0.520991 HPV testing 0.581414 cervical cancer mortality 0.721474 cervical cancer screening 0.742524 CIN 0.553434 Natl Cancer Inst 0.615845 cervical cancer 0.995918 cervical squamous cell 0.556962 cervical human papillomavirus 0.547211 HPV DNA arm 0.52076 cervical cytology cotesting 0.564531 human papillomavirus 0.694632 cervical cancer death 0.561576 high-grade cervical lesions 0.559164	cervical cancer incidence 0.597514 atypical squamous cells 0.549121 et al. 0.515402 women 0.616944 cervical cytology 0.628179 cervical cancer detection 0.553165 PUBMED Abstract 0.530353 invasive cervical cancer 0.658472 repeat HPV DNA 0.513096 cervical screening programmes 0.542296 conventional cervical smear 0.513052 primary cervical cancer 0.570395 abnormal cervical cancer 0.542326 cervical cancer risks 0.549122 Abstract 0.599358 Cervical cancer control 0.552963 cervical cytologic abnormalities 0.517315 invasive cervical cancers 0.51155 cervical intraepithelial neoplasia 0.648604 hpv dna test 0.564095 squamous intraepithelial lesions 0.555418 cervical cytologic 0.523009 cervical cancer cases 0.567527 Cervical cancer risk 0.551241	CLICK HERE
1389	National Cancer Institute	Html	en	Breast Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of ductal carcinoma in situ, lobular carcinoma in situ, and invasive breast cancer.	adjuvant chemotherapy 0.413465 primary breast cancer 0.408571 Breast cancer prognosis 0.425608 MammaPrint breast cancer 0.413079 breast cancer patient 0.414699 Engl J Med 0.524403 Breast Cancer Family 0.427508 Breast Cancer Linkage 0.421472 Breast Cancer Cooperative 0.407872 15-year breast cancer 0.406317 her2-positive breast cancer 0.442543 early-stage breast cancer 0.442314 Radiat Oncol Biol 0.416027 triple-negative breast cancer 0.428166 node-positive breast cancer 0.499527 breast cancer patients 0.48801 operable breast cancer 0.439264 Natl Cancer Inst 0.634346 benign breast disease 0.41282 receptor-negative breast cancer 0.410906 surgical adjuvant breast 0.46168 -negative breast cancer 0.425377 breast cancer death 0.425817 invasive breast cancer 0.473025 et al. 0.549932	contralateral breast cancer 0.442652 early breast cancer 0.60357 early-onset breast cancer 0.418149 stage breast cancer 0.414667 lobular breast cancer 0.425161 age-specific breast cancer 0.41613 PUBMED Abstract 0.428161 node-negative breast cancer 0.45155 T1 breast cancer 0.412562 breast cancer risk 0.490957 International Breast Cancer 0.418134 Abstract 0.568891 Clin Oncol 0.680872 Danish Breast Cancer 0.425148 breast cancer 0.97463 Oncol Biol Phys 0.418084 Breast Cancer Trialists 0.422554 breast cancer mortality 0.404968 Breast Cancer Study 0.420746 oestrogen-receptor-positive breast cancer 0.416419 breast cancer incidence 0.439577 subsequent breast cancer 0.429086 advanced breast cancer 0.411746 Breast Cancer Res 0.494855	CLICK HERE
1391	National Cancer Institute	Html	en	Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Wilms tumor.	wilms tumors 0.503727 wilms tumor 0.905843 Wilms tumor development 0.5254 Wilms tumor genetics 0.517912 Wilms Tumor Study-5 0.477443 familial Wilms tumour 0.446601 favorable-histology wilms tumor 0.511105 stage II Wilms 0.439212 unilateral Wilms tumor 0.553115 Wilms tumor patients 0.529584 favorable histology Wilms 0.460427 bilateral Wilms patients 0.460054 Tumor Study Group 0.595101 contralateral Wilms tumor 0.495745 Wilms tumor-Aniridia syndrome 0.439108 preoperative wilms tumor 0.505524 bilateral wilms tumor 0.635902 stromal-type Wilms tumor 0.516983 Wilms tumor surveillance 0.49553 beckwith-wiedemann syndrome 0.43423 inoperable Wilms tumor 0.526248 Group/National Wilms Tumor 0.47873 Low-risk Wilms Tumor 0.474612 histology Wilms tumors 0.433526 Wilms Tumor Study 0.723902	Wilms tumor screening 0.479856 wilms tumor rupture 0.501052 et al. 0.499553 wilms tumor predisposition 0.521351 histology Wilms tumor 0.504567 Wilms tumours 0.453209 COG Wilms tumor 0.518219 SIOP Wilms Tumor 0.504401 Wilms tumour 0.50015 bilateral Wilms tumor. 0.45063 Pediatr Blood Cancer 0.440629 wilms tumor suppressor 0.492641 nonsyndromic Wilms tumor 0.493832 Metachronous bilateral Wilms 0.434751 National Wilms Tumor 0.736085 Med Genet 0.447601 Abstract 0.531043 Clin Oncol 0.453706 familial Wilms tumor. 0.444435 Wilms tumor locus 0.521817 Familial Wilms tumor 0.495658 non-WT1-syndromic Wilms tumor 0.488494 Wilms Tumor Study-3 0.478135 Wilms tumor susceptibility 0.497583	CLICK HERE
1528	National Cancer Institute	Html	en	Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors.	currently used treatment 0.491433 treatment 0.80031 abnormal cells 0.591776 cancer treatment 0.491469 ovaries 0.553108 abdomen 0.566902 body cavity 0.495458 NCI-supported cancer 0.497228 tissue 0.516419 cancer cells 0.493195 body 0.515176 Cancer Information Service 0.489344 low malignant potential 0.507879 PDQ cancer information 0.620272 clinical trial search 0.566415 uterus 0.498028 treatment clinical trials 0.555055 National Cancer Institute 0.572253 clinical trials 0.964888 tumor cells 0.695966 Treatment Options section 0.484079 cancer information summary 0.567078 clinical trial 0.741404 new treatment 0.564234	disease 0.554973 malignant potential tumor 0.900634 new treatments 0.489278 patients 0.603036 earlier clinical trials 0.497766 clinical trials database 0.496798 peritoneal cavity 0.517264 Potential Tumors Treatment 0.491558 treatment clinical trial 0.511947 PDQ Adult Treatment 0.504736 NCI PDQ cancer 0.507801 ovary 0.536161 cancer clinical trials 0.578107 tests 0.498811 stage 0.7416 malignant potential tumors 0.621847 fallopian tubes 0.57444 treatment options 0.549139 Treatment Editorial Board 0.533517 cancer information summaries 0.487894 comprehensive cancer information 0.488381 cancer 0.721628 standard treatment 0.552748	CLICK HERE
1709	National Cancer Institute	Html	en	Genetics of Kidney Cancer (Renal Cell Cancer) (PDQ®)–Health Professional Version	Hereditary kidney cancer (renal cell cancer) syndromes include von Hippel-Lindau disease, hereditary leiomyomatosis and renal cell cancer, Birt-Hogg-Dubé syndrome, and hereditary papillary renal carcinoma. Learn about the genetics, clinical manifestations, and management of these hereditary cancer syndromes in this expert-reviewed summary.	Renal cell cancer 0.417461 sporadic renal cell 0.38738 renal pelvis cancer 0.39949 hereditary renal tumors 0.379064 renal tumors 0.424533 solid-enhancing renal masses 0.375815 marginal renal function. 0.376092 Hippel-Lindau tumor suppressor 0.449329 cell renal cell 0.422508 renal replacement therapy 0.383629 renal parenchymal sparing 0.388349 von Hippel-Lindau families 0.43492 Hippel-Lindau tumour suppressor 0.410095 von hippel-lindau disease 0.900395 von hippel-lindau 0.920724 von Hippel Lindau 0.387864 advanced von Hippel-Lindau 0.430231 salvage renal surgery 0.382297 Hippel-Lindau protein mutants 0.39948 von Hippel-Lindau ubiquitylation 0.442871 small renal mass 0.378802 von Hippel-Lindau gene 0.462044 et al. 0.556118 small renal masses 0.392859 sporadic renal masses 0.379735	renal functional outcomes 0.377613 papillary renal cell 0.383702 renal carcinomas 0.373668 renal tubules 0.373542 hereditary renal cancer 0.400308 renal disease 0.379225 ocular von Hippel-Lindau 0.464552 renal medulla 0.3796 VHL 0.386773 von Hippel-Lindau tumor 0.479006 tumor suppressor gene 0.380161 Bilateral renal cell 0.380325 Abstract 0.55535 Hippel-Lindau disease tumor 0.448931 von Hippel-Lindau patients 0.465787 sporadic renal carcinoma. 0.386645 renal cell carcinoma 0.660911 Hippel-Lindau gene mutations 0.398567 Hippel-Lindau protein promotes 0.402255 von Hippel-Lindau protein 0.50858 von hippel-lindau syndrome 0.558083 clear-cell renal cell 0.409767 Hum Genet 0.372826 von Hippel-Lindau mutation 0.438746	CLICK HERE
1837	National Cancer Institute	Html	es	Tratamiento del cáncer de pene (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de pene.	Horenblas S 0.510336 Nielsen OS 0.509173 Compton CC 0.557867 therapy with cisplatin 0.51114 alta incidencia 0.509039 Russo P 0.509584 Ta Carcinoma 0.513251 radical inguinal lymphadenectomy 0.511322 invasive carcinoma 0.512611 Urologic Cancer 0.517007 7th ed 0.565184 linfadenectomía profiláctica 0.526988 Radiat Oncol Biol 0.519915 Verrucous carcinoma 0.511779 papillomavirus-associated penile squamous 0.511778 epidermoid carcinoma 0.511036 retrospective analysis 0.533675 papillomavirus dna 0.511396 8th ed 0.50889 típico carcinoma 0.513162 Waters WB 0.509049 Lindegaard JC 0.509948 human papillomavirus 0.555341 Catalona WJ 0.510454 Javadpour N 0.50987	estadio iv 0.51387 Neoadjuvant therapy with 0.511141 Surg Pathol 0.512914 Microscopically controlled surgery 0.510476 Perez CA 0.516876 Reda DJ 0.508824 Harty JI 0.510648 Surgical treatment 0.514704 Cancer Staging Manual 0.614394 carcinoma with 0.51364 treatment with 0.51195 carcinoma basaloide 0.513292 New York 0.574898 Lundbeck FA 0.510525 sentinel node biopsy 0.508574 Oncol Biol Phys 0.520345 squamous cell carcinomas 0.95738 Ornellas AA 0.50861 Byrd DR 0.554153 Zhang ZF 0.510317 treated with 0.512687 Acta Oncol 0.509033 Tis Carcinoma 0.513411 AJCC Cancer Staging 0.617972	CLICK HERE
2041	National Cancer Institute	Html	es	Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga.	antecedentes familiares 0.40081 Schistosoma haematobium 0.417111 Visuals Online 0.357081 PDQ Exámenes 0.503031 Physician Data Query 0.696072 Estados Unidos 0.406708 túbulos renales 0.432914 prevención revisa 0.368302 sistema urinario masculino 0.518469	largo plazo 0.406946 vejiga almacena 0.840919 información ayuda 0.374743 biopsia.ampliar cistoscopia 0.431465 National Cancer Institute 0.400139 siguientes riesgos 0.364163 pelvis renal 0.934476 Instituto Nacional 0.483729	CLICK HERE
3855	National Cancer Institute	Html	es	Tratamiento del cáncer sin daño al corazón	Investigadores de los campos de oncología y de cardiología están trabajando para encontrar formas de impedir, manejar y posiblemente aun revertir los efectos secundarios cardiovasculares de ciertas terapias del cáncer.	doctora minasian 0.420648 Toxicidad Cardiovascular 0.397361 funciones cardíacas 0.389495 oncología comunitaria suncoast 0.499346 Estudio PREDICT 0.431531 doctores edward t.h 0.46464 Eileen Dimond 0.383363 Más gente 0.39382 Cancer Center 0.835847 Instituto Nacional 0.378255 evento coronario 0.384904 necesaria investigación 0.396051 Gregory Hundley 0.381508 uso del lisinopril 0.382252 NCI.“El NCI 0.483538 mayores aumentos 0.393722 bloqueador beta 0.384896 cuestión provocativa número 0.450757 alto riesgo 0.61435 doctor saro armenian 0.462785 Mayo Clinic 0.37936 enfermedad isquémica cardíaca 0.538111 carvedilol fosfato 0.395021 Anderson Cancer Center 0.780116	editorial anexo 0.379604 Dana-Farber Cancer Institute 0.454758 Brigada Comunitaria 0.385219 efectos tardíos 0.687242 Pimprapa Vejpongsa 0.386075 Wake Forest Baptist 0.436151 doctor gregory t 0.449856 futuras investigaciones 0.386679 efectos secundarios cardíacos.Sustancias 0.621707 MD Anderson Cancer 0.78917 médicos oncólogos 0.393733 supervivientes adultos 0.958505 cardiopatía coronaria 0.411854 Jude Children´s Research 0.445325 corto plazo 0.380257 Vanderbilt-Ingram Cancer Center 0.454856 doctora sarah c 0.467574 doctora pooja p 0.468177 Estudio USF 0.426971 doctor javid moslehi 0.464739 doctor w 0.384312 largo tiempo 0.383822 doctora lori minasian 0.500028 doctor moslehi 0.395708	CLICK HERE
14599	National Cancer Institute	Html	en	PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer	Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection.	fewer neck dissections 0.480753 different PET-imaging systems 0.416156 trial 0.383529 surgical dissection 0.49691 surgery group 0.546725 equivocal response 0.373027 main goal 0.370069 standard first-line therapy 0.446339 2-year overall survival 0.421723 results 0.372041 PET-CT–guided surveillance 0.384586 PET-CT group 0.386097 advanced squamous cell 0.578344 standardized PET imaging 0.419169 heterogeneous study population 0.413368 2,200-per-patient cost savings 0.413451 study groups 0.42202 patients 0.610711 metabolic abnormalities 0.37096 Dr. Malik 0.419332 health care costs 0.414997 lymph nodes 0.375275 overall survival rates 0.55552 surveillance group 0.491325	chemoradiation 0.396529 Shakun Malik 0.372291 nodal metastases 0.375714 positron-emission tomography 0.373068 magnetic resonance imaging 0.431542 Cancer Research UK 0.422638 Technology Assessment Programme 0.42519 United States 0.41309 N3 disease 0.374897 fewer operations 0.382441 randomized controlled PET-NECK 0.429823 PET-CT imaging 0.485125 advanced imaging techniques 0.434786 neck dissection 0.819668 PET-CT surveillance 0.497223 neck dissection patients 0.544115 Hisham Mehanna 0.370962 long-term results 0.369928 trial results 0.371832 United Kingdom 0.369679 cancer treatment centers 0.428263 substantial complications 0.369604 New England Journal 0.442645 clinical usefulness 0.371858	CLICK HERE
15878	National Cancer Institute	Html	es	Antineoplastones (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer.	with antineoplaston a2 0.218822 Investigación Burzynski 0.22067 with antineoplastons 0.246694 Exp Clin Res 0.800411 antineoplastón a10 0.397658 Initial clinical study 0.211468 prostate with antineoplaston 0.217616 Purified Antineoplaston Fractions 0.215376 antineoplaston a10 0.272621 pacientes nimustina 0.213052 antineoplastons a10 0.222443 Clin Proc 0.222323 study with antineoplaston 0.218319 Veinte pacientes 0.213707 antineoplastón a3 0.224113 chemoradiation therapy with 0.212987 Oncol Rep 0.240747 Soc Exp Biol 0.215807 patients with 0.222048 Physiol Chem Phys 0.238091 antineoplastones a10 0.278317 pacientes respuesta 0.221956 Burzynski SR 0.970231 Kubove E 0.284007 US Patent 0.217212	antineoplaston a10 with 0.212999 Antineoplaston treatment 0.211591 patients with five 0.213355 Arch Pharm Res 0.21496 Drugs Exp Clin 0.778727 Kumabe T 0.215619 Instituto Burzynski 0.215357 antineoplaston as2-1 0.25609 Toxicology studies 0.237437 antineoplastones a2 0.223629 antineoplastón as2-5 0.218066 inhibitory effect 0.218192 Antineoplaston Study Group 0.215678 antineoplastón as2-1 0.256718 clinical study with 0.213829 antineoplaston as2-5 0.211859 Tsuda H 0.416032 clinical studies 0.21939 Proc Soc Exp 0.216295 with five years 0.211921 Burzynski B 0.287937 Mohabbat MO 0.210993 Exp Biol Med 0.216836 Integr Cancer Ther 0.216474	CLICK HERE